| [December 18, 2017] |
 |
Cambridge BioMarketing Discusses Outlook for Gene Therapy and CAR-T Treatments in 2018
Cambridge
BioMarketing, an Ashfield company, part of UDG Healthcare plc and
the world's leading rare disease agency, today announced five
predictions for 2018 related to the pharmaceutical, life sciences and
marketing industries:
-
It will be more important than ever for healthcare companies to
incorporate the hyperpersonalized experience in marketing and
communications: As personalized medicine continues to take hold,
consumers expect the same approach with healthcare communications.
Targeting and retargeting messaging to be hyperpersonalized will be
key. As technology becomes more sophisticated, marketers have a
responsibility to communicate and deliver messages that line up with
audience expectations, behavior and media literacy. - Annemarie
Crivelli, Director of Digital
-
Gene therapies and CAR-T 'kinks' will still need to be worked out: In
2017 we saw landmark breakthroughs in advanced genetic therapies, such
as viral mediated gene transfer and CAR-T therapies. That momentum
will not slow in 2018, but reimbursement and access issues will
continue to be a challenge even as more advanced genetic therapies
garner approvals. For example, CAR-T agents and the procedures and
hospitalization time for these therapies are quite expensive; only the
top health centers have the facilities and skills necessary to
successfully implement these advanced therapies. The patient demand is
there, the approval is there, but effectiveness in clinical practice
requires access and reimbursement. The commercial challenges for these
scientific breakthroughs remain despite the approvals. - Sam
Falsetti, PhD, Head of Medical Strategy and Product Innovation
-
Pharmaceutical companies will take a deeper dive into the 'rare
side' of common diseases: In 2018, the market will continue to see
an increased focus on specific mutations or subtypes within larger or
more common tumor types such as breast cancer. - Michael Tonzola,
Group Management Supervisor, Oncology
-
b>Pharmaceutical companies will leverage patients to transform data
points into human stories: The patient voice will be more
important than ever when it comes to regulatory decisions during
advisory committee meetings. In 2017, we witnessed the power of
patient testimonials around the approval of the Spark
gene therapy treatment for a form of childhood blindness. In 2018, we
will see more pharma companies tapping the experts who can best
explain the often life-changing benefits of a treatment: the patient.
- Maureen Franco, Chief Executive Officer
-
The rise of tech for better partnerships: In 2018, we'll see
improved patient outcomes not only because of new treatments, but also
thanks to more effective care coordination among patients, physicians,
nurses, and care partners. Patients embarking on new treatments will
be better empowered to take charge of their well-being while
physicians and nurses will be better connected to their patients and
other care providers with the support of enhanced digital connections
and mobile apps. This will be particularly impactful in the rare
disease community, where multidisciplinary teams are the norm. - Julianne
Dunphy, PhD, Director, Medical Strategy
About Cambridge BioMarketing
Founded in 2001, Cambridge
BioMarketing is a U.S.-based communications agency specializing in rare
orphan diseases with over 100 employees. Headquartered in Cambridge, MA
with offices in Oakland, CA (News - Alert), Cambridge BioMarketing is an industry
leader in orphan drug launches, advising pharmaceutical companies with
an integrated focus on both traditional healthcare professional (HCP)
programs and direct-to-patient work. In partnering with predominantly
pharmaceutical and biotech customers, the agency's goal is to bring
physicians, specialists, and patient communities together on behalf of
clients to transform human health in the face of
devastating, under-appreciated disease states. Cambridge BioMarketing's
primary service offerings include: launch readiness support; digital
strategy; market analytics; integrated marketing; patient identification
and acquisition; medical affairs support; line extensions and patient
retention and adherence programs.
For more information, please go to: http://cambridgebmg.com/
About Ashfield:
Ashfield Commercial & Medical Services, part
of UDG Healthcare plc, is a global leader in providing outsourced
healthcare services to pharmaceutical, device and biotech companies. The
company has more than 7,000 employees, operates in 23 countries across
Europe, North America, South America and Asia and works with more than
250 companies, including all of the world's top 25 pharmaceutical
companies. Its mission is to partner with its clients, improving lives
by helping healthcare professionals and patients get the medicines,
knowledge and support they need.
Ashfield's provides contract sales teams, customer service reps, medical
science liaison officers, remote detailing, nurse educators, medical
information, healthcare communications, market access, market research,
training, event management, digital, creative and pharmacovigilance
services.
For more information, go to www.ashfieldhealthcare.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005149/en/
[ Back To TMCnet.com's Homepage ]
|
